drugset / Trial / NCT01910870
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
NaSingle-groupOpen-labelTreatment
Summary
To evaluate response rate of cisplatin - metronomic cyclophosphamide treatment.
Timeline
- Start
- 2013-07
- Primary completion
- 2016-09
- Completion
- 2016-09
Outcome
Outcome not reported
Stopped (Enrollment): “Because of difficulties in recruiting”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 150 mg | Oral |